Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
SLDB's Cash-to-Debt is ranked higher than
78% of the 859 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. SLDB: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
SLDB' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
SLDB's Interest Coverage is ranked higher than
75% of the 648 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.08 vs. SLDB: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SLDB' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 42.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -74.74
SLDB's ROE % is ranked lower than
92% of the 832 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.94 vs. SLDB: -74.74 )
Ranked among companies with meaningful ROE % only.
SLDB' s ROE % Range Over the Past 10 Years
Min: -74.74  Med: 0 Max: 0
Current: -74.74
-74.74
0
ROA % -53.53
SLDB's ROA % is ranked lower than
90% of the 871 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. SLDB: -53.53 )
Ranked among companies with meaningful ROA % only.
SLDB' s ROA % Range Over the Past 10 Years
Min: -89.22  Med: -44.72 Max: -11.45
Current: -53.53
-89.22
-11.45
ROC (Joel Greenblatt) % -1450.16
SLDB's ROC (Joel Greenblatt) % is ranked lower than
94% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.23 vs. SLDB: -1450.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SLDB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11316.81  Med: -7562.5 Max: -1450.16
Current: -1450.16
-11316.81
-1450.16
GuruFocus has detected 2 Warning Signs with Solid Biosciences Inc SLDB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SLDB's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SLDB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Solid Biosciences Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325411    SIC: 2836
Compare:SZSE:300452, TSXV:FIRE, TSE:4517, HKSE:00932, XKRX:000020, TSE:4597, XKRX:214390, XKRX:008490, BOM:530239, TSE:4594, ASX:CAN, XKLS:7081, XKRX:002250, ASX:AC8, BOM:532612, OCSE:VELO, SZSE:300636, NAS:SNDX, NAS:DRRX, SZSE:002817 » details
Headquarter Location:USA
Solid Biosciences Inc is a life science company engaged in developing therapies for Duchenne muscular dystrophy. Its product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles.

Solid Biosciences Inc is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Solid Biosciences, lead product candidate the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. In the assistive device program, the company focuses on producing a wearable assistive device for patients with DMD.

Top Ranked Articles about Solid Biosciences Inc

Solid Biosciences to Present at the Credit Suisse Healthcare Conference
Solid Biosciences to Present at the Chardan Genetic Medicines Conference
Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors
Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline – SLDB
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Solid Biosciences Inc. of Class Action Lawsuit and Upcoming Deadline – SLDB
SOLID BIOSCIENCES LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Solid Biosciences Inc. To Contact The Firm
SLDB $100,000 Threshold: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Solid Biosciences Inc. Investors
SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
Solid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting

Ratios

vs
industry
vs
history
PB Ratio 5.60
SLDB's PB Ratio is ranked lower than
86% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.64 vs. SLDB: 5.60 )
Ranked among companies with meaningful PB Ratio only.
SLDB' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.7
Current: 5.6
0
23.7
EV-to-EBIT -9.76
SLDB's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.85 vs. SLDB: -9.76 )
Ranked among companies with meaningful EV-to-EBIT only.
SLDB' s EV-to-EBIT Range Over the Past 10 Years
Min: -110.21  Med: 0 Max: 0
Current: -9.76
-110.21
0
EV-to-EBITDA -9.97
SLDB's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.24 vs. SLDB: -9.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
SLDB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -110.63  Med: 0 Max: 0
Current: -9.97
-110.63
0
Current Ratio 13.95
SLDB's Current Ratio is ranked higher than
96% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SLDB: 13.95 )
Ranked among companies with meaningful Current Ratio only.
SLDB' s Current Ratio Range Over the Past 10 Years
Min: 2.6  Med: 6.27 Max: 18.95
Current: 13.95
2.6
18.95
Quick Ratio 13.95
SLDB's Quick Ratio is ranked higher than
96% of the 855 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. SLDB: 13.95 )
Ranked among companies with meaningful Quick Ratio only.
SLDB' s Quick Ratio Range Over the Past 10 Years
Min: 2.6  Med: 6.27 Max: 18.95
Current: 13.95
2.6
18.95

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.25
SLDB's Price-to-Net-Cash is ranked higher than
66% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.41 vs. SLDB: 6.25 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SLDB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.55  Med: 8.23 Max: 12.51
Current: 6.25
1.55
12.51
Price-to-Net-Current-Asset-Value 6.11
SLDB's Price-to-Net-Current-Asset-Value is ranked lower than
55% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. SLDB: 6.11 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SLDB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.53  Med: 8.13 Max: 12.22
Current: 6.11
1.53
12.22
Price-to-Tangible-Book 5.75
SLDB's Price-to-Tangible-Book is ranked lower than
79% of the 749 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. SLDB: 5.75 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SLDB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.49  Med: 7.78 Max: 11.52
Current: 5.75
1.49
11.52
Earnings Yield (Greenblatt) % -10.21
SLDB's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.31 vs. SLDB: -10.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SLDB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.42  Med: 0 Max: 0
Current: -10.21
-19.42
0

More Statistics

EPS (TTM) $ -1.61
52-Week Range $6.83 - 54.84
Shares Outstanding (Mil)35.43

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $) -77 -103 -115
EBITDA (Mil $) -77 -101 -111
EPS ($) -2.28 -2.66 -2.72
EPS without NRI ($) -2.28 -2.66 -2.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}